Table 1.
Basic information of included studies.
| Author/yr | Disease type | Age (yr) | Platelet count (, x109/L) | Number of cases | Intervention | Treatment (wk) | Outcome indicators |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | ||||
| Beiyuexian, 2015[35] | ITP | 35.7 ± 12.4 | 33.42 ± 10.2 | 156.9 ± 52.4 | 141.5 ± 61.7 | 55 | 55 | CFA | Hormone therapy | 4 | (a)(b)(c) |
| Chenming, 2012[36] | ITP | 35.2 | 33.3 | 81.5 ± 16.48 | 69.5 ± 5.42 | 41 | 23 | CFA | Hormone therapy | 5 | (a) |
| Donghanzhi, 2020[37] | Squamous lung cancer | 54 | 54 | 189.22 ± 55.86 | 156.38 ± 59.88 | 25 | 25 | CFA | Conventional chemotherapy | 2 | (a)(d) |
| Duzunming A., 2018[38] | Lymphoma | 56 | 55 | 173.94 ± 51.7 | 123.85 ± 46.67 | 41 | 41 | CFA | G-CSF | 3 | (a)(c)(e)(f) |
| Duzunming B., 2018[39] | Lung cancer | 62 | 60 | 217.26 ± 19.74 | 111.59 ± 20.41 | 60 | 60 | CFA | G-CSF | 4 | (a)(b)(c)(e)(f) |
| Hedi, 2020[40] | ITP | 46.28 ± 5.19 | 48.79 ± 6.14 | 121.56 ± 21.95 | 78.22 ± 16.44 | 52 | 52 | CFA | Hormone therapy | 4 | (a)(b)(c) |
| Huangzhenhua, 2013[41] | Uremia | 50.8 | 49.6 | 193.61 ± 11.03 | 99.68 ± 12.09 | 12 | 12 | CFA | Conventional Hemostatic Drugs | 4 | (a) |
| Jiaxiaohui, 2013[42] | Systemic lupus erythematosus | 35.2 ± 18.4 | 36.8 ± 16.7 | 97 ± 38.5 | 72 ± 36.7 | 30 | 30 | CFA | Leucogen Tablets | 4 | (a)(d)(e) |
| Kangjide, 2013[43] | ITP | 30.9 ± 10.8 | 31.5 ± 7.5 | 144.6 ± 45.3 | 132.5 ± 50.8 | 45 | 45 | CFA | Hormone therapy | 4 | (a)(b)(c) |
| Linwei, 2022[44] | Leukemia | 16.82 ± 3.32 | 17.73 ± 3.07 | 57.86 ± 4.72 | 38.25 ± 3.94 | 40 | 40 | CFA | rhIL-11 | 2 | (a)(c)(d)(e) |
| Linwenyuan, 2019[45] | ITP | 36 | 36 | 147.3 ± 69.8 | 138.3 ± 58.2 | 34 | 41 | CFA | Hormone therapy | 8 | (a)(b) |
| Liudan, 2015 [46] |
ITP | 30.8 ± 5.1 | 31.4 ± 5.2 | NR | NR | 26 | 26 | CFA | Hormone therapy | 6 | (b)(c) |
| Liufeng, 2011[47] | Aplastic anemia | 33 | 33 | 76 ± 15 | 50 ± 14 | 49 | 43 | CFA | Hormone therapy | 12 | (a)(b)(e) |
| Liuke, 2012 [48] |
ITP | 30 | 30 | 145 ± 60.1 | 140 ± 50.1 | 49 | 49 | CFA | Hormone therapy | 8 | (a) |
| Liuxueru, 2016[49] | Esophageal cancer | 58 | 56 | NR | NR | 24 | 24 | CFA | Leucogen Tablet Vitamin B tablet |
4 | (b)(c)(e) |
| Lixiansong, 2013[50] | ITP | 35 | 35 | NR | NR | 14 | 14 | CFA | Anti-HP conventional treatment drugs | 4 | (b) |
| Lixiaohong, 2013[51] | ITP | 65 | 65 | 86.00 ± 44.74 | 64.26 ± 29.22 | 31 | 31 | CFA | Herbs for clearing heat and cooling the blood | 12 | (a)(b) |
| Luoyihui, 2013[52] | Cirrhosis of the liver | 56 | 56 | NR | NR | 50 | 50 | CFA | Leucogen Tablet | 4 | (b) |
| Majun, 2017 [53] |
ITP | 32.9 | 32.9 | 79.90 ± 43.95 | 57.87 ± 24.25 | 60 | 60 | CFA | Coffee acid tablet mockups | 4 | (a)(b)(c) |
| Mengdeqian, 2018[54] | Systemic lupus erythematosus | 39.4 ± 17.6 | 37.3 ± 14.1 | 128.70 ± 52.55 | 102.50 ± 35.70 | 31 | 32 | CFA | Hormone therapy | 4 | (a)(c)(e) |
| Mengdeqian, 2021[55] | Dryness syndrome | 44.6 ± 11.7 | 42.4 ± 10.5 | 156.03 ± 87.92 | 123.72 ± 64.38 | 36 | 36 | CFA | Hormone therapy | 4 | (a)(c)(e) |
| Miudong, 2013[56] | ITP | 41.32 ± 7.38 | 41.32 ± 7.38 | NR | NR | 15 | 15 | CFA | Conventional chemotherapy | NR | (b) |
| Panbo, 2013 [57] |
Chemotherapy prevention | 44.6 ± 11.7 | 42.4 ± 10.5 | 178.8 ± 40.3 | 89.4 ± 30.5 | 41 | 41 | CFA | Conventional chemotherapy | 3 | (a) |
| Pangying, 2012[58] | lymphadenoma | 55.6 | 53 | 223 ± 121 | 143.5 ± 94.5 | 30 | 30 | CFA | Batilol tablet | 2 | (a)(c)(e) |
| Pengaihua, 2015[59] | Breast Cancer | 48 ± 8.47 | 49 ± 9.37 | 327 ± 67.55 | 274 ± 48.02 | 30 | 30 | CFA | G-CSF | 3 | (a)(c)(d)(e)(f) |
| Tangtianbi, 2017[60] | Tuberculosis | 43.4 ± 12.3 | 41.4 ± 11.2 | 118.77 ± 39.72 | 93.23 ± 19.29 | 29 | 28 | CFA | Leucogen Tablet | 3 | (a)(b)(c) |
| Wanghaicun, 2016[61] | Breast Cancer | 44.23 ± 6.26 | 45.49 ± 6.51 | 319.00 ± 72.32 | 286.00 ± 62.52 | 40 | 40 | CFA | G-CSF | 2 | (a)(b)(d)(e) |
| Wangjun, 2013[62] | ITP | NR | NR | 113 ± 26.61 | 79.7 ± 27.36 | 20 | 20 | CFA | Hormone therapy | 4 | (a) |
| Xinxiaohai, 2015[63] | Chemotherapy prevention | 53.2 ± 2.1 | 53.2 ± 2.1 | 178.9 ± 40.2 | 89.2 ± 30.4 | 40 | 40 | CFA | Conventional chemotherapy | 3 | (a) |
| Xudan, 2019 [64] |
ITP | 42.7 ± 3.1 | 44.8 ± 4.4 | NR | NR | 40 | 40 | CFA | Leucogen Tablet | 12 | (b) |
| Yangxi, 2019 [65] |
Children ITP | 7.1 ± 0.6 | 7.2 ± 0.8 | 91.52 ± 21.31 | 80.88 ± 20.65 | 49 | 49 | CFA | Hormone therapy | 4 | (a)(b) |
| Zhangxiaomeng, 2022[66] | Hematologic Tumors in children | 7.5 ± 2.31 | 7.5 ± 2.61 | 201.25 ± 45.52 | 152.25 ± 41.52 | 49 | 49 | CFA | G-CSF | 2 | (a)(c)(d)(e)(f) |
| Zhangxuejuan, 2013[67] | ITP | 37.3 ± 10.92 | 36.7 ± 9.17 | 86 ± 12 | 36 ± 11 | 33 | 27 | CFA | Hormone therapy | 4 | (a)(b) |
| Zhaobianfeng, 2017[68] | Lung cancer | 55.1 | 54.3 | 227.9 ± 100.5 | 193.5 ± 84.2 | 32 | 32 | CFA | Batilol tablet | 2 | (a)(c)(e) |
| Zhoucaixia, 2022[69] | Aplastic anemia | 37.58 ± 6.89 | 36.48 ± 6.43 | 81.39 ± 0.54 | 67.84 ± 2.58 | 25 | 25 | CFA | Hormone therapy | 12 | (a)(b) |
T is the test group and C is the control group. Outcome indicators: (a) platelet count; (b) clinical efficacy; (c) incidence of adverse effects; (d) neutrophil count; (e) leucocyte count; and (f) myelosuppression.
CFA = control group on the basis of caffeic acid tablets, G-CSF = recombinant human granulocyte colony-stimulating factor, ITP = immune thrombocytopenic purpura, NR = not reported, rhIL-11 = platelet-producing drugs.